Key result
Cardioprotective drugs, including beta-blockers, ACE inhibitors, statins, and dexrazoxane, show promise in reducing heart failure incidence and managing chemotherapy-induced cardiotoxicity.
Why the study?
Chemotherapy-induced cardiotoxicity presents a major clinical challenge, and further research is needed to confirm the effectiveness and optimal use of cardioprotective medications.
Do cardioprotective agents (beta-blockers, ACE inhibitors, statins, dexrazoxane) reduce chemotherapy-induced cardiotoxicity in cancer patients?
Do cardioprotective agents (beta-blockers, ACE inhibitors, statins, dexrazoxane) reduce chemotherapy-induced cardiotoxicity in cancer patients?
Cardioprotective drugs such as beta-blockers, ACE inhibitors, statins, and dexrazoxane hold significant promise in managing chemotherapy-induced cardiotoxicity and improving cardiac outcomes for cancer patients.
Background: Chemotherapy-induced cardiotoxicity (CIC) is a significant challenge in cancer treatment, leading to heart failure and myocardial infarction. With rising cancer survival rates, the long-term cardiovascular health of survivors has gained importance. While several cardioprotective medications have been studied to mitigate chemotherapy's harmful effects on the heart, more research is needed to confirm their effectiveness and optimal use. Methodology: This review synthesizes evidence on cardioprotective drugs in managing CIC. The authors conducted a comprehensive literature search of peer-reviewed articles, clinical trials, and meta-analyses published between January 2000 and May 2024. Studies were selected based on relevance, quality, and focus on mechanisms, efficacy, and clinical outcomes of cardioprotective agents such as beta-blockers, ACE inhibitors, ARBs, statins, and dexrazoxane. Results and discussion: Cardioprotective medications show potential in alleviating the impact of chemotherapy on heart function. Beta-blockers and ACE inhibitors effectively reduce heart failure incidence and improve cardiac outcomes. Statins, with their anti-inflammatory and antioxidative properties, and dexrazoxane, which reduces anthracycline-induced cardiotoxicity, also show promise. However, variability in study designs, patient groups, and chemotherapy treatments complicates the establishment of standardized treatment protocols. Conclusion: Cardioprotective drugs hold significant promise in managing CIC and improving cardiac outcomes for cancer patients. Current evidence supports the efficacy of beta-blockers, ACE inhibitors, statins, and dexrazoxane. Further research is needed to establish standardized protocols, evaluate long-term safety, and optimize treatment timing. Integrating cardioprotective strategies into oncological care can enhance the quality of life and prognosis for cancer survivors.
No takes yet. Share an insight, caveat, or question.
Al-Hasnawi et al. (2024) conducted a review in Chemotherapy-induced cardiotoxicity (CIC). Cardioprotective drugs (beta-blockers, ACE inhibitors, ARBs, statins, dexrazoxane) was evaluated. Cardioprotective drugs, including beta-blockers, ACE inhibitors, statins, and dexrazoxane, show promise in reducing heart failure incidence and managing chemotherapy-induced cardiotoxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: